Molecular Imaging of the Lung- Phase 1 (R01)

archived

This FOA, issued by the National Heart, Lung and Blood Institute (NHLBI), National Institute of Health, invites Research Project Grant (R01) applications to develop novel in vivo imaging reagents and technologies such as molecular probes that target pathways or cells involved in development and pathobiology of pulmonary diseases. In Phase I investigators will identify appropriate molecular targets with relevance to lung health and diseases, develop the appropriate molecular probes, in combination with innovative imaging approaches, and validate the developed probes in cells and in vivo animal models. NHLBI anticipates announcing a companion FOA for a Phase II that will be released at a later date, to support studies to extend molecular imaging methods to human studies for clinical applications in lung disease. Both phases will be open competitions. The long-term goal is to use molecular imaging to facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress in cell-specific drug delivery and therapies.

High